Ikarian Capital’s MaxCyte MXCT Stock Holding History

Ikarian Capital’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-137,958	Closed	-$964K	–	177
2022 Q1	$964K	Buy	137,958 +7,958	+6%	+$54.3K	0.13%	101
2021 Q4	$1.32M	Sell	130,000 -20,000	-13%	-$215K	0.2%	85
2021 Q3	$1.83M	Buy	+150,000	New	+$2.26M	0.13%	131

Other funds holding MXCT

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RGI

River Global Investors London, United Kingdom $515M AUM 24.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Ikarian Capital's MXCT Position: Q2 2022 in Review

Ikarian Capital sold out of MaxCyte (MXCT) in Q2 2022, closing a stake of 137,958 shares — an estimated $964K sold.

Ikarian Capital first reported a position in MXCT in Q3 2021 and held it in 3 quarters. The position peaked at $1.83M in Q3 2021. 102 funds tracked by Wall St. Rank hold MXCT as of Q2 2022.

Ikarian Capital reported no remaining MaxCyte position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 137,958 MaxCyte shares in Q2 2022, an estimated $964K.
Ikarian Capital first reported a position in MaxCyte in Q3 2021 and held it in 3 quarters.
Ikarian Capital's MaxCyte position peaked at $1.83M in Q3 2021.
102 funds tracked by Wall St. Rank held MaxCyte as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.